This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-65. (Cancelled)

66. (New) A compound formed by the process comprising the steps of:

reacting a compound having the Formula:



wherein R5-R8 are each, independently, hydrogen, hydroxyl, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, nitro, cyano or amide,

with a 2-hydroxyalcohol having the formula:



wherein R1-R4 are each, independently, selected from the group consisting of H, substituted and unsubstituted C_1-C_6 alkyl, substituted and unsubstituted C_1-C_6 alkenyl, substituted and unsubstituted C_1-C_6 alkoxy, substituted and unsubstituted C_1-C_6 alkoxycarbonyl, substituted and unsubstituted C_1-C_6 acyl, -$(CH_2)_n$-amino, -$(CH_2)_n$-aryl, -$(CH_2)_n$-heterocycle, and -$(CH_2)_n$-phenyl; n is an integer from 1 to 10,

and, treating said compound formed said reaction with strong acid and exposing the reaction to air.

67. (New) The compound formed by the process in claim 66, wherein said strong acid is concentrated sulfuric acid or trifluoroacetic acid.

68. (New) The compound formed by the process in claim 66, the compound having the formula:



or pharmaceutically acceptable salts thereof, or a regioisomeric mixture thereof, wherein

R1-R4 are each, independently, selected from the group consisting of H, substituted and unsubstituted C_1-C_6 alkyl, substituted and unsubstituted C_1-C_6 alkenyl, substituted and unsubstituted C_1-C_6 alkoxy, substituted and unsubstituted C_1-C_6 alkoxycarbonyl, substituted and unsubstituted C_1-C_6 acyl, -$(CH_2)_n$-amino, -$(CH_2)_n$-aryl, -$(CH_2)_n$-heterocycle, and -$(CH_2)_n$-phenyl; or one of R1 or R2 and one of R3 or R4 form a fused ring, wherein the ring has 4-8 ring members;

R5-R8 are each, independently, hydrogen, hydroxyl, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, nitro, cyano or amide; and

n is an integer from 1 to 10,
wherein R1, R2, R3, R4, R5, R6, R7 and R8 are not each H.

69. (New) The compound formed by the process in claim 68, wherein R1 and R2 are alkyl, R3-R4 are, independently, H, OH, halogen, alkyl, alkoxy, substituted or unsubstituted acyl, substituted alkenyl or substituted alkyl carbonyl, and R7-R10 are each hydrogen.

70. (New) The compound formed by the process in claim 68, wherein R1 and R2 are each hydrogen, one of R3 and R4 is methyl and the other is hydrogen and R5-R8 are each hydrogen.

71. (New) The compound formed by the process in claim 68, wherein one of R1 and R2 is methyl and the other is hydrogen, one of R3 and R4 is methyl and the other is hydrogen and R5-R8 are each hydrogen.

72. (New) The compound formed by the process in claim 68, wherein one of R1 and R2 is

methyl and the other is hydrogen, one of R3 and R4 is hydroxymethyl and the other is hydrogen and R5-R8 are each hydrogen.

73. (New) The compound formed by the process in claim 68, wherein one of R1 and R2 is methyl and the other is hydrogen, R3 and R4 are each methyl and R5-R8 are each hydrogen.

74. (New) The compound formed by the process in claim 68, the compound having the formula:



or pharmaceutically acceptable salt or a regioisomeric mixture thereof.

75. (New) The compound formed by the process in claim 68, the compound having the formula:



or pharmaceutically acceptable salt or a regioisomeric mixture thereof.

76. (New) The compound formed by the process in claim 68, the compound having the formula:



or pharmaceutically acceptable salt or a regioisomeric mixture thereof.

77. (New) The compound formed by the process in claim 68, the compound having the formula:



or pharmaceutically acceptable salt or a regioisomeric mixture thereof.

78. (New) The compound formed by the process in claim 68, the compound having the formula:



or pharmaceutically acceptable salt or a regioisomeric mixture thereof.

79. (New) A pharmaceutical composition comprising a therapeutically effective amount of the compound formed by the process in claim 66 in combination with a pharmaceutically acceptable carrier.